Market research
6ZY.F Zynerba Pharmaceuticals, Inc
F EUR Not available
Latest close
Loading market data…
Test a moving-average rule with historical data.
Market facts
- Market cap
- 66M
- P/E ratio
- Not available
- Analyst target
- 7.63
- Dividend yield
- 0.0%
- Beta
- 1.19
Profile
Company facts
- Exchange
- F
- Currency
- EUR
- Sector
- Not available
- Industry
- Not available
- ISIN
- Not available
- Market cap
- 66M
- P/E ratio
- Not available
- Analyst target
- 7.63
- Dividend yield
- 0.0%
- Beta
- 1.19
About
About Zynerba Pharmaceuticals, Inc
Zynerba Pharmaceuticals, Inc. operates as a clinical stage specialty pharmaceutical company. The company focuses on developing pharmaceutically produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. It is developing Zygel, a pharmaceutically produced cannabidiol formulated as a permeation-enhanced gel for transdermal delivery. The company was formerly known as AllTranz, Inc. and changed its name to Zynerba Pharmaceuticals, Inc. in August 2014. Zynerba Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Devon, Pennsylvania. As of October 10, 2023, Zynerba Pharmaceuticals, Inc. operates as a subsidiary of Harmony Biosciences Holdings, Inc.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the 6ZY.F discussion.
5 years, 6 months ago
Zynerba Pharmaceuticals, Inc is currently in a long term uptrend where the price is trading 13.1% above its 200 day moving average.
From a valuation standpoint, the stock is 13.6% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 1134.7.
Zynerba Pharmaceuticals, Inc's total revenue sank by nan% to $0 since the same quarter in the previous year.
Its net income has increased by 10.2% to $-10M since the same quarter in the previous year.
Finally, its free cash flow grew by 6.2% to $-7M since the same quarter in the previous year.
Based on the above factors, Zynerba Pharmaceuticals, Inc gets an overall score of 4/5.